

Company: Asahi Intecc Co., Ltd.
Representative: Masahiko Miyata, President & CEO
(Securities code: 7747, First section of
Tokyo Stock Exchange and Nagoya Stock Exchange)
Contact: Mizuho Ito,
Member of Board & CFO, General Manager of Administration
(TEL. +81-52-768-1211)

Notice regarding an agreement with Medtronic for the exclusive distribution of Asahi Intecc's Neurovascular Guidewire and Catheter in the United States

Asahi Intecc Group announces that ASAHI INTECC USA, INC., a 100% subsidiary of Asahi Intecc, has reached an agreement with Medtronic plc for the exclusive distribution of Asahi Intecc's Neurovascular guidewire and catheter in the US market.

Following is the detail of the agreement.

I. Outline

In the US market, Asahi Intecc Group has sold Neurovascular guidewire and catheter directly since January 2013, however Asahi Intecc Group is going to shift to distributor sales through Medtronic plc, that has enough sales network to cover US major hospitals all over the country.

Asahi Intecc Group has significant market share, over 60%, of Neurovascular guidewire and catheter in Japan with its product advantages. In the overseas countries centered on the US, Asahi Intecc Group is aiming at increasing revenues through expanding its sales and gaining market share of Neurovascular guidewire and catheter in the growing field.

II. Schedule

- Date of resolution of board of directors : November 14, 2018
- Date of the conclusion of contract : November 14, 2018

III. Main Contents of Contract

- Terms of contract : Starting December 10, 2018
- Exclusive distribution of Asahi Intecc's Neurovascular guidewire and catheter in the United States and its territories
- Products : ASAHI neurovascular guidewire "CHIKAI" series
ASAHI neurovascular guide catheter "FUBUKI"

IV. Summary of Medtronic

C o m p a n y N a m e : Medtronic plc

H e a d O f f i c e : 20 On Hatch, Lower Hatch Street, Dublin 2, Ireland

E s t a b l i s h m e n t : In 1949

N u m b e r o f E m p l o y e e s : About 86,000 persons

S a l e s : 29,953 million dollars (fiscal year 2018)

B u s i n e s s O p e r a t i o n s : Development, production and sale of medical devices

U R L : www.medtronic.com

V. Impact on Sales Revenue

Limited impact to sales is expected through June 2019; thus there will be no change to announced forecasts.